financetom
Business
financetom
/
Business
/
Acadia Healthcare Q1 Adjusted Earnings, Revenue Increase; Reaffirms 2024 Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Acadia Healthcare Q1 Adjusted Earnings, Revenue Increase; Reaffirms 2024 Outlook
May 2, 2024 1:06 AM

03:56 AM EDT, 05/02/2024 (MT Newswires) -- Acadia Healthcare ( ACHC ) reported Q1 adjusted earnings late Wednesday of $0.84 per diluted share, up from $0.75 a year earlier.

Analysts polled by Capital IQ expected $0.80.

Revenue for the quarter ended March 31 was $768.1 million, up from $704.3 million a year ago. Analysts surveyed by Capital IQ expected $779.3 million.

The company reiterated its full-year 2024 outlook of adjusted EPS to be in a range of $3.40 to $3.70 and revenue to come in between $3.18 billion and $3.25 billion. Analysts polled by Capital IQ expect normalized EPS of $3.56 on revenue of $3.22 billion.

Price: 72.00, Change: -0.99, Percent Change: -1.36

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
PrairieSky Says Received TSX Approval for Renewed Normal Course Issuer Bid
PrairieSky Says Received TSX Approval for Renewed Normal Course Issuer Bid
May 30, 2025
08:38 AM EDT, 05/30/2025 (MT Newswires) -- PrairieSky Royalty Ltd. ( PREKF ) announced Friday that the Toronto Stock Exchange has accepted the notice of its intention to commence a normal course issuer bid. The company noted that on April 14, 2025, it announced its intention to seek TSX approval to renew its NCIB for an additional one-year period. The...
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data
May 30, 2025
Regeneron Pharmaceuticals ( REGN ), Inc. and Sanofi SA ( SNY ) on Friday announced results from two Phase 3 trials of itepekimab in chronic obstructive pulmonary disease (COPD) patients. Phase 3 AERIFY-1 trial evaluating itepekimab in adults who were former smokers with inadequately controlled COPD met the primary endpoint of significantly reducing moderate or severe acute exacerbations by 27% compared...
Mainstreet Equity Gets Approval for Stock Buyback
Mainstreet Equity Gets Approval for Stock Buyback
May 30, 2025
08:29 AM EDT, 05/30/2025 (MT Newswires) -- Mainstreet Equity ( MEQYF ) on Friday said the Toronto Stock Exchange has accepted its notice to buy back up to 475,359 shares for one year beginning on June 3. The company did not buy back any shares during its current normal course issuer bid, which ends on June 2. ...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved